Novel compounds have shown promising data on IM-refractory GISTs in the early phases of clinical trials9,10; however, new drug development in advanced GISTs still mainly targets the KIT inhibition despite the emergence of immunotherapy in other types of cancers. This evidence concerns the gene KIT and cancer.